Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 171

1.

Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.

Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC.

Breast Cancer Res. 2005;7(6):R1028-35. Epub 2005 Oct 25.

PMID:
16280056
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.

Cho EY, Choi YL, Han JJ, Kim KM, Oh YL.

Pathol Int. 2008 Jan;58(1):17-25.

PMID:
18067636
[PubMed - indexed for MEDLINE]
3.

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.

Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B.

Mod Pathol. 2005 Aug;18(8):1027-33.

PMID:
15920544
[PubMed - indexed for MEDLINE]
Free Article
4.

The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.

Latta EK, Tjan S, Parkes RK, O'Malley FP.

Mod Pathol. 2002 Dec;15(12):1318-25.

PMID:
12481013
[PubMed - indexed for MEDLINE]
Free Article
5.

EGFR amplification and lack of activating mutations in metaplastic breast carcinomas.

Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, Simpson PT, Jones C, Swift S, Mackay A, Reis RM, Hornick JL, Pereira EM, Baltazar F, Fletcher CD, Ashworth A, Lakhani SR, Schmitt FC.

J Pathol. 2006 Aug;209(4):445-53.

PMID:
16739104
[PubMed - indexed for MEDLINE]
6.

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.

Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MM.

Mol Cancer Ther. 2008 Apr;7(4):944-51. doi: 10.1158/1535-7163.MCT-07-0570.

PMID:
18413808
[PubMed - indexed for MEDLINE]
Free PMC Article
7.
8.

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.

Jimenez RE, Wallis T, Tabasczka P, Visscher DW.

Mod Pathol. 2000 Jan;13(1):37-45.

PMID:
10658908
[PubMed - indexed for MEDLINE]
Free Article
9.

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.

Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z.

Mod Pathol. 2002 Jun;15(6):657-65.

PMID:
12065780
[PubMed - indexed for MEDLINE]
Free Article
10.

HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.

Ricardo SA, Milanezi F, Carvalho ST, Leitão DR, Schmitt FC.

J Clin Pathol. 2007 Sep;60(9):1001-5. Epub 2006 Dec 8.

PMID:
17158643
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.

Bhargava R, Naeem R, Marconi S, Luszcz J, Garb J, Gasparini R, Otis CN.

Hum Pathol. 2001 Dec;32(12):1344-50.

PMID:
11774167
[PubMed - indexed for MEDLINE]
12.

Chromosome 7 aneusomy in metaplastic breast carcinomas with chondroid, squamous, and spindle-cell differentiation.

Gwin K, Lezon-Geyda K, Harris L, Tavassoli FA.

Int J Surg Pathol. 2011 Feb;19(1):20-5. doi: 10.1177/1066896909334127. Epub 2009 May 1.

PMID:
19411277
[PubMed - indexed for MEDLINE]
13.

Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas.

Mrhalova M, Plzak J, Betka J, Kodet R.

Neoplasma. 2005;52(4):338-43.

PMID:
16059652
[PubMed - indexed for MEDLINE]
14.

Detection of human epidermal growth factor receptor 2 protein and gene in fine needle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue sections?

Sumiyoshi K, Shibayama Y, Akashi S, Nohara T, Iwamoto M, Kobayashi T, Nishimura H, Yoshinaka R, Harada T, Tanigawa N.

Oncol Rep. 2006 Apr;15(4):803-8.

PMID:
16525662
[PubMed - indexed for MEDLINE]
16.

EGFR expression and activation are common in HER2 positive and triple-negative breast tumours.

Koletsa T, Kotoula V, Karayannopoulou G, Nenopoulou E, Karkavelas G, Papadimitriou CS, Kostopoulos I.

Histol Histopathol. 2010 Sep;25(9):1171-9.

PMID:
20607659
[PubMed - indexed for MEDLINE]
17.

Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains.

Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G.

Histopathology. 2003 Oct;43(4):354-62.

PMID:
14511254
[PubMed - indexed for MEDLINE]
18.

EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.

Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA.

Gynecol Oncol. 2006 Jan;100(1):101-6. Epub 2005 Sep 12.

PMID:
16157366
[PubMed - indexed for MEDLINE]
19.

Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.

Gouvêa AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H.

Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):103-8.

PMID:
16540740
[PubMed - indexed for MEDLINE]
20.

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.

Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y.

Mod Pathol. 2004 Aug;17(8):895-904.

PMID:
15143334
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk